{"entity":{"id":"immuneering","kind":"company","name":"Immuneering","aka":["Immuneering Corporation"],"tldr":"Immuneering is a United States-based biotechnology company running 2 late-stage cancer trials of Atebimetinib in pancreatic ductal adenocarcinoma, melanoma and non-small-cell lung cancer.","summary":"Immuneering, based in Cambridge, the United States, is a biotechnology company. Immuneering is a biotechnology company developing oncology treatments based on 'Deep Cyclic Inhibitors', a pulsed dosing approach to MAPK-pathway inhibition intended to reduce cancer resistance while improving tolerability. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing Atebimetinib in pancreatic ductal adenocarcinoma, melanoma and non-small-cell lung cancer. The largest, NCT07562152 (Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma), plans to enrol 510 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.immuneering.com"},{"label":"ClinicalTrials.gov: trials led by Immuneering","url":"https://clinicaltrials.gov/search?lead=Immuneering%20Corporation"},{"label":"Pipeline page","url":"https://www.immuneering.com/pipeline"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["pancreatic","melanoma","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["atebimetinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05585320"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Cambridge","country":"US","companyType":"biotech","website":"https://www.immuneering.com","investors":[],"funding":[]},"route":"/companies/immuneering/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"atebimetinib","kind":"drug","name":"Atebimetinib","route":"/drugs/atebimetinib/"}],"trial":[{"id":"nct05585320","kind":"trial","name":"A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors","route":"/trials/nct05585320/"},{"id":"nct07562152","kind":"trial","name":"Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","route":"/trials/nct07562152/"}]}}